FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of Immunologists' (AAI) IMMUNOLOGY2025. Designed to streamline workflows, accelerate discoveries, and enhance efficiency, FSP technology will be the focus of a variety of demonstrations, educational workshops and tutorials at these prominent industry gatherings. Flow cytometry plays a crucial role in both research and clinical studies, and Cytek is at the forefront of making this powerful technology more accessible and scalable. By empowerin

FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024 Net loss in the year ended December 31, 2024 was $6.0 million compared to net loss of $12.1 million in th

FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek BiosciencesCytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next ge

FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Participating on Tuesday, February 11 and Wednesday, February 12, 2025 Raymond James 46th Annual Institutional Investors Conference in Orlando, FLPresentation on Monday, March 3, 2025, at 3:25 p.m. Eastern Time / 12:25 p.m. Pacific Time TD Cowen 45th Annual Health Care Conference in Boston, MAFireside chat on Wednesday, March 5, 2025, at 10:30 a.m. Eastern Time / 7:30 a

FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek's 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million. Expected fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The appreciation of the

FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysi

FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. The new repurchase program is authorized to commence on January 1, 2025 and remain in effect until December 31, 2025 unless extended or shortened by the Board of Directors. Any repurchases under the 2025 repurchase program will be made in the open market and/or in private

FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY. Cytek management is scheduled to participate in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next gen

SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)

8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

DEFA14A - Cytek Biosciences, Inc. (0001831915) (Filer)

DEF 14A - Cytek Biosciences, Inc. (0001831915) (Filer)

S-8 - Cytek Biosciences, Inc. (0001831915) (Filer)

8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

SC 13D/A - Cytek Biosciences, Inc. (0001831915) (Subject)

FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-

FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. "Philippe's extensive global sales and marketing experience as an executive at several life science companies, incl

FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Todd Garland as Chief Commercial Officer, Cytek Biosciences, Inc. Garland's appointment is effective immediately, reporting directly to Dr. Wenbin Jiang, Chairman and CEO of Cytek Biosciences. "I have long admired Cytek's advanced technology and products, and I am particularly pleased to join the company because I believe Cytek has a real opportunity to become the premier company in the cell analysis industry," commented Garland. Garland's prior professional career spans BD Biosciences, CareFusion and Cardinal

TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00

Raymond James initiated coverage of Cytek Biosciences with a rating of Mkt Perform

Morgan Stanley reiterated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $18.00 from $27.00 previously

Piper Sandler resumed coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $20.00

Cowen resumed coverage of Cytek Biosciences with a rating of Outperform

Cowen initiated coverage of Cytek Biosciences with a rating of Outperform

Morgan Stanley initiated coverage of Cytek Biosciences with a rating of Equal-Weight

Morgan Stanley initiated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $26.00